A short, 60 seconds read that summarises 4 handpicked articles that are worth reading about:
What is the price of a child’s life? The affordability of rare disease therapies
Correlating value with price in the US oncology market: Key learnings for manufacturers
Europe: IPCEI on health to promote development of gene and cell therapies
France: HAS extends early access authorisation to additional patients
AIFA reform is a landmark change which propels Italy towards expedited drug approvals and improved a...
The MHRA grants conditional approval to Casgevy, the first-ever CRISPR gene-editing therapy for sick...
Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.
Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.